

10 May 2019


Re: Official Information Act

Dear 

I am responding on behalf of Hauora Tairāwhiti (Tairāwhiti DHB) to your OIA Request of 9 May regarding clinical drug trials.

Our response to your request:

The number of clinical drug trials your DHB hosted in the 2017/2018 financial year + ongoing trials in 2019.

Could figures please be broken-down by:

- The number of sponsored clinical trials involving devices and pharmaceuticals.
- Phase 1 first-man-in clinical trials and phase 2a/b safety and efficacy trials, phase 3 broader efficacy trials and phase 4 post-marketing surveillance. And whether these trials are
- investigator-initiated or industry-sponsored commercially contracted trials.
- Investigator-initiated studies of non-therapeutic interventions, e.g. new diagnostics or new applications of existing diagnostics.
- Investigator-initiated observational studies including epidemiologic studies.

Can you please also provide the aggregate income figure your DHB obtained from trials conducted in the 2017/2018 financial year.

Hauora Tairāwhiti has not been involved in any clinical drug trials in the above mentioned time frame.

If you are not satisfied with this response you may contact the Office of the Ombudsmen, phone 0800 802 602.

Please note this response, or an edited version of this response, may be published on the Hauora Tairāwhiti DHB website. Your personal/identifying information will be redacted from any responses published.

If you feel that there are good reasons why your response should not be made publicly available, we will be happy to consider this.

Ngā mihi,

Briar Hunter
Communications Advisor
Hauora Tairāwhiti